Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC)

B. I. Rini,Daniel J. George,M. D. Michaelson,J. E. Rosenberg,Ronald M. Bukowski,J.A. Sosman,Walter M. Stadler,K. Margolin,Thomas E. Hutson,Charles M. Baum

Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC)

2006

B. I. Rini
Daniel J. George
M. D. Michaelson
J. E. Rosenberg
Ronald M. Bukowski
J.A. Sosman
Walter M. Stadler
K. Margolin
Thomas E. Hutson
Charles M. Baum

4522 Background: Sunitinib malate (SU11248) is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptor (VEGFR) family, platelet-derived growth factor rec...

Keywords:

Bevacizumab
Refractory
Renal cell carcinoma
Sunitinib malate
Cancer research
Medicine
Pathology
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations